1.93
16.97%
+0.28
Revelation Biosciences Inc stock is currently priced at $1.93, with a 24-hour trading volume of 111.07K.
It has seen a +16.97% increased in the last 24 hours and a -8.41% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.66 pivot point. If it approaches the $1.82 resistance level, significant changes may occur.
Previous Close:
$1.65
Open:
$1.65
24h Volume:
111.07K
Market Cap:
$3.15M
Revenue:
-
Net Income/Loss:
$-120.30K
P/E Ratio:
-3.5085
EPS:
-0.5501
Net Cash Flow:
$-7.29M
1W Performance:
+5.46%
1M Performance:
-8.41%
6M Performance:
+166.91%
1Y Performance:
+83.81%
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650 800 3717
Address
4660 La Jolla Village Drive, Suite 100, San Diego
Revelation Biosciences Inc Stock (REVB) Latest News
Post-Trade Analysis: Revelation Biosciences Inc (REVB) Slides -1.79, Closing at 1.65 – DWinneX - The Dwinnex
The Dwinnex
Bears are Losing Control Over Revelation Biosciences, Inc. (REVB), Here's Why It's a 'Buy' Now - Yahoo Movies Canada
Yahoo Movies Canada
Bears are Losing Control Over Revelation Biosciences, Inc. (REVB), Here's Why It's a 'Buy' Now - Yahoo New Zealand News
Yahoo New Zealand News
Rhinitis Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by ... - openPR
openPR
Rhinitis Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by ... - openPR
openPR
Rhinitis Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by ... - Barchart
Barchart
Revelation Biosciences Inc Stock (REVB) Financials Data
Revelation Biosciences Inc (REVB) Net Income 2024
REVB net income (TTM) was -$120.30 thousand for the quarter ending December 31, 2023, a +98.89% increase year-over-year.
Revelation Biosciences Inc (REVB) Cash Flow 2024
REVB recorded a free cash flow (TTM) of -$7.29 million for the quarter ending December 31, 2023, a +35.06% increase year-over-year.
Revelation Biosciences Inc (REVB) Earnings per Share 2024
REVB earnings per share (TTM) was -$211.15 for the quarter ending December 31, 2023, a +70.35% growth year-over-year.
Revelation Biosciences Inc Stock (REVB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
TIDMARSH GEORGE F | Director |
Oct 16 '23 |
Sale |
0.66 |
10,957 |
7,243 |
42,096 |
TIDMARSH GEORGE F | Director |
Oct 16 '23 |
Sale |
0.65 |
1,845 |
1,199 |
27,771 |
TIDMARSH GEORGE F | Director |
Sep 28 '23 |
Sale |
0.69 |
1,429 |
986 |
42,096 |
TIDMARSH GEORGE F | Director |
Sep 18 '23 |
Sale |
0.74 |
4,000 |
2,960 |
39,348 |
TIDMARSH GEORGE F | Director |
Sep 15 '23 |
Sale |
0.73 |
9,500 |
6,935 |
43,348 |
TIDMARSH GEORGE F | Director |
Sep 14 '23 |
Sale |
0.75 |
12,000 |
9,000 |
52,848 |
About Revelation Biosciences Inc
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Cap:
|
Volume (24h):